Literature DB >> 35236771

The Synthetic Cannabinoid WIN55,212-2 Can Disrupt the Golgi Apparatus Independent of Cannabinoid Receptor-1.

Joshua Lott1, Emily M Jutkiewicz1, Manojkumar A Puthenveedu2.   

Abstract

The synthetic cannabinoid WIN55,212-2 (WIN) is widely used as a pharmacological tool to study the biologic activity of cannabinoid receptors. In contrast to many other cannabinoid agonists, however, WIN also causes broad effects outside of neurons, such as reducing inflammatory responses, causing cell cycle arrest, and reducing general protein expression. How exactly WIN causes these broad effects is not known. Here we show that WIN partially disrupts the Golgi apparatus at nanomolar concentrations and fully disperses the Golgi apparatus in neuronal and non-neuronal cells at micromolar concentrations. WIN55,212-3, the enantiomer of WIN; JWH-018, a related alkylindole; or 2-arachidonoylglycerol, an endocannabinoid, did not cause Golgi disruption, suggesting that the effect was specific to the chirality of WIN. WIN treatment also perturbed the microtubule network. Importantly, WIN disrupted the Golgi in primary cortical neurons derived from mice where cannabinoid receptor-1 (CB1) was genetically knocked out, indicating that the effects were independent of CB1 signaling. The Golgi dispersion could not be explained by WIN's action on peroxisome proliferator-activated receptors. Our results show that WIN can disrupt the Golgi apparatus independent of CB1 in cultured cells. These effects could contribute to the unique physiologic effects that WIN exhibits in neuronal behavior, as well as its role as an antiproliferative and anti-inflammatory agent. SIGNIFICANCE STATEMENT: The synthetic cannabinoid WIN55,212-2 (WIN), widely used to investigate the cannabinoid system, also shows unique broader effects at cellular and organismal levels compared to endogenous cannabinoids. Our study shows that WIN can disrupt the Golgi apparatus and the microtubule network in multiple cell types, independent of cannabinoid receptors. These results could explain how WIN reduces surface levels of proteins and contributes to the unique physiological effects observed with WIN.
Copyright © 2022 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35236771      PMCID: PMC9092469          DOI: 10.1124/molpharm.121.000377

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.054


  47 in total

1.  Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses.

Authors:  R I Wilson; R A Nicoll
Journal:  Nature       Date:  2001-03-29       Impact factor: 49.962

2.  PPAR-gamma inhibitors as novel tubulin-targeting agents.

Authors:  Katherine L Schaefer
Journal:  Expert Opin Investig Drugs       Date:  2007-07       Impact factor: 6.206

3.  Effects of GABAA receptors in nucleus cuneiformis on the cannabinoid antinociception using the formalin test.

Authors:  Junjie Chen; Parisa Hasanein; Alireza Komaki; Siamak Yari
Journal:  Psychopharmacology (Berl)       Date:  2021-03-13       Impact factor: 4.530

4.  Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals.

Authors:  T Ohno-Shosaku; T Maejima; M Kano
Journal:  Neuron       Date:  2001-03       Impact factor: 17.173

5.  Combined antiproliferative effects of the aminoalkylindole WIN55,212-2 and radiation in breast cancer cells.

Authors:  Sean M Emery; Moureq R Alotaibi; Qing Tao; Dana E Selley; Aron H Lichtman; David A Gewirtz
Journal:  J Pharmacol Exp Ther       Date:  2013-11-20       Impact factor: 4.030

Review 6.  Pharmacological actions of cannabinoids.

Authors:  R G Pertwee
Journal:  Handb Exp Pharmacol       Date:  2005

Review 7.  Endocannabinoid signaling and synaptic function.

Authors:  Pablo E Castillo; Thomas J Younts; Andrés E Chávez; Yuki Hashimotodani
Journal:  Neuron       Date:  2012-10-04       Impact factor: 17.173

8.  Striatal CB1 and D2 receptors regulate expression of each other, CRIP1A and δ opioid systems.

Authors:  Lawrence C Blume; Caroline E Bass; Steven R Childers; George D Dalton; David C S Roberts; Jasmine M Richardson; Ruoyu Xiao; Dana E Selley; Allyn C Howlett
Journal:  J Neurochem       Date:  2013-01-31       Impact factor: 5.372

9.  The Synthetic Cannabinoid WIN 55,212-2 Elicits Death in Human Cancer Cell Lines.

Authors:  Leonie Müller; Arlo Radtke; Jennifer Decker; Michael Koch; Gazanfer Belge
Journal:  Anticancer Res       Date:  2017-11       Impact factor: 2.480

10.  Differential regulation of behavioral tolerance to WIN55,212-2 by GASP1.

Authors:  Lene Martini; Dawn Thompson; Viktor Kharazia; Jennifer L Whistler
Journal:  Neuropsychopharmacology       Date:  2010-02-17       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.